SCHEMBL81407

SCHEMBL81407

Clc1ccc(CCCBr)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.52
IGF1R P08069 1/20 0.50
ALOX15 P16050 1/20 0.50
KCNH2 Q12809 4/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28811325 0.93 TAAR1 (0.47) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL1008937 0.93 IGF1R (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL11460578 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL7562217 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL5596095 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL7217191 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL7464785 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL7562067 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL7614753 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E
SCHEMBL8071211 0.91 KCNH2 (0.53) TAAR1IGF1RALOX15KCNH2HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116640104-B Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2024-04-02 CN claimed
CN-116640104-A Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2023-08-25 CN claimed
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function Lee Moffitt Cancer Center and Research Institute, Inc. (US) 2026-03-03 US disclosed
US-20250136581-A1 SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) 2025-05-01 US disclosed
CN-115703765-B Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2025-02-28 CN disclosed
EP-4447963-A1 SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2024-10-23 EP disclosed
US-20240336568-A1 SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2024-10-10 US disclosed
CN-118715015-A Selective PHD1 inhibitor compounds, compositions and methods of use 阿克比治疗有限公司 2024-09-27 CN disclosed
EP-4385988-A1 SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2024-06-19 EP disclosed
CN-116640104-B Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2024-04-02 CN disclosed
CN-116640104-B Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2024-04-02 CN disclosed
EP-0349062-A1 Quinoline ether alkanoic acid MERCK FROSST CANADA INC. (CA) 1990-01-03 EP disclosed
EP-0347766-A2 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments Dr. Karl Thomae GmbH (DE) 1989-12-27 EP disclosed
WO-1989004819-A1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES LABORATOIRES LUCIEN (FR) 1989-06-01 WO disclosed
EP-0226636-B1 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 1989-02-08 EP disclosed
EP-0299684-A1 Heterocyclic Compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-01-18 EP disclosed
EP-0250198-A2 Bis-azolyl compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-12-23 EP disclosed
EP-0226636-A1 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS. BOEHRINGER MANNHEIM GMBH (DE) 1987-07-01 EP disclosed
WO-1987000521-A2 NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS BOEHRINGER MANNHEIM GMBH (DE) 1987-01-29 WO disclosed
US-4222765-A HERBICIDES FOR PADDY FIELDS KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1980-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12564583-B2 Small molecules against cereblon to enhance effector T cell function CRBN, CD4, ICOS TAAR1 1569/4885IGF1R 2393/4885ALOX15 1093/4885
US-20250136581-A1 SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GABRA5, SLC6A11, GABRA1 TAAR1 1317/4885IGF1R 2444/4885ALOX15 808/4885
US-20240336568-A1 SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN1, EGLN2 TAAR1 3728/4885IGF1R 2149/4885ALOX15 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.